comparemela.com

Latest Breaking News On - Her2 positive breast cancer - Page 1 : comparemela.com

T-DXd Maintains Survival Advantage Over Physician s Choice of Therapy in HER2+ Metastatic Breast Cancer

Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.

Soult ukpyolsiSouth koreaDaiichi sankyoBae kimDaehwa pharmaAsan medical centerEnsol bioscience incUniversity of ulsanBreast cancer annual congressCancer annualSung bae kimTrastuzumab deruxtecanHer2 positive breast cancer

Breast-Conserving Therapy Bests Mastectomy After Preoperative Systemic Therapy in HER2+ Breast Cancer

Following preoperative systemic therapy, breast-conserving therapy led to superior OS vs mastectomy in HER2-positive breast cancer.

United statesAiham qdaisatDepartment of emergency medicineUniversity of texas md anderson cancer centerDivision of internal medicineLancet regional healthLancet regionalEmergency medicineInternal medicineCancer centerD anderson cancer centerBreast conserving therapyHer2 positive breast cancer

Tripathy Outlines Where the HER2+ Early-Stage Breast Cancer Landscape Stands

Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.

United statesUniversity of texas md anderson cancer centerDepartment of breast medical oncologyDebu tripathyAnnual miami breast cancerBreast medical oncologyCancer centerAnnual miami breast cancer conferenceReal world strategiesMetastatic breast cancerHer2 early stage breast cancer landscape41st annual miami breast cancer conference2024 miami breast cancer conferenceAdvancements in her2 testing methodsHer2 positive breast cancer

HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

San antonioUnited statesSaraa hurvitzTrastuzumab emtansinePrimary analysisDouble blind phasePreviously treatedMetastatic breastPartnership withAntonio breast cancer symposiumBreast cancerHer2 metastatic breast cancerHer2 positive metastatic breast cancerHer2 breast cancerHer2 positive breast cancerHer2climb 02

The Latest Findings on Major Breast Cancer Trials

Here's a roundup of the most recent data from five phase 3 trials presented at SABCS 2023.

United statesSan franciscoJo chienGabriel hortobagyiUniversity of californiaMd anderson cancer centerUniversity of frankfurtAntonio breast cancer symposiumMedical newsCancer centerSibylle loiblBreast cancerAlignant breast neoplasmBreast carcinomaBiologic therapyAntineoplastic drug

vimarsana © 2020. All Rights Reserved.